Abstract:SUMMARY Exenatide is a synthetic version of exendin-4 which shares several glucoregulatory activities with the mammalian hormone, glucagon-like peptide-1 (GLP-1).In this study, a novel formulation of goblet cell-targeting nanoparticles for oral exenatide delivery was developed. Oral administration of exenatide nanoparticles to the db/db mice could reduce the blood glucose concentration by approximately 40%. INTRODUCTION Exendin-4 is an incretin mimetic found in the lizad saliva which is in the new class of anitbiabetic agents. In clinical trails, exenatide exhibited glucoregulatory effects such as glucose-dependent stimulation of insulin secretion, suppression of inappropriately elevated glucagon secretion, and slowing of gastric emptying. So far, there isn’t any proper route of administration except subcutaneous (SC) injections which need to be given frequently and could cause pain. It is high time that new administration routes should be investigated. The oral route is always considered to be the most convenient and comfortable means of drug administration for patients. Oral administration of exenatide would be beneficial to diabetic patients, as it not only alleviates the pain caused by injections, but can also mimic the physiological fate of insulin and may provide a better glucose homeostasis. The major problem faced in delivering a therapeutic peptide through the oral route is poor oral bioavailability due to incomplete and/or erratic absorption through the gastrointestinal tract (GIT), degradation of the drug or drug carriers due to varying pH of the stomach and enzymatic degradation. It has been reported that the use of colloidal carriers such as nanoparticles and nanocapsules can be a promising way to improve the oral bioavailability of peptides and proteins [1] . Chitosan has already been used in the form of nanoparticles and nanocapsules aimed at improving the transmucosal delivery of drugs through different mucosal surfaces [2]. In this study, we used the goblet cell-targeting peptide (CSK) connect to chitosan to prepare the nanoparticle. EXPERIMENTAL METHODS The nanoparticles were prepared using ionotropic gelation method. Briefly, exenatide was dissolved in distilled water (2mg/ml) and was added to the CSK peptide modified chitosan (CSK-chitosan) solution, and then, 2.5mg/ml tripolyphsophate (TPP) solution was added dropwisely to CSK-chitosan solution (1mg/ml) at a ratio of 0.15:1 under magnetic stirring. Then the solution was stirred at 500 rpm for 40min, and yielded an opalescent suspension which had obvious Tyndall phenomenon. Characterization of NPs: the size and zeta potential of the drug loaded nanoparticles were characterized with a Zeta Potential/Particle Sizer (NICOMP TM 380ZLS, NICOMP). Entrapment efficiency of drug loaded NPs: The amount of encapsuled exenatide was measured by sephadex G50 gel column. Briefly, a 4cm gel column was made by 5ml syringe with a little piece of filter paper blocked the exits and sephadex G50 was pre-swelled with boiled distilled water. The nanoparticles and the free exenatide have the different retention time and the nanoparticles will eluted at a faster speed because of the larger size. The eluted nanoparticles was damaged by adding an amount of acetic acid. The amount of exenatide in the nanoparticles was measured by a reversephase high performance liquid chromatography (HPLC) method (Agilent 1260 series, CA, USA). Pharmacological and hypoglycemic studies: the db/db mice were chosen as type IIdiabetes model and administrated with the following formulations: oral administration with physiological Saline (20ml/kg), chitosan NPs (30μg/kg), CSK-chitosan NPs (30μg/kg). Blood samples were collected from the tail veins of the mice prior to drug administration and at different time intervals (1, 2, 4, 6, 8, 10 and 12h) after dosing. And then determinate the blood glucose with glucometer (ACCU-CHEK®). The total decrease (D%) of blood glucose were calculated using a modification formula as follow: D%=[AUC(physiological saline)-AUC(test)]/ AUC(physiological saline)*100 RESULTS AND DISCUSSION The characteristics of blank and drug loaded NPs were shown in Fig.1. It was shown that both of the NPs made with chitosan and CSKchitosan were uniform and the size were 120± 20nm.The particles were nearly spherical and smooth. Fig.1.TEM micrograph of the chitosan NPs and CSK-chitosan NPs The pharmacological effects of chitosan NPs and CSK-chitosan NPs were evaluated on db/db mice after oral administration. As shown in Fig.2, both of chitosan NPs and CSK-chitosan NPs exhibited relatively strong hypoglycemic effects as compared with exenatide solution at 2h and 4h after administration. Moreover, with the modification of CSK peptide, CSK-chitosan NPs showed a better hypoglycemic effect with the blood glucose value reduced to 60% of the original. The chitosan NPs group and the physiological saline group of the mice exhibited stress hyperglycemia symptoms after administration of the drug and this phenomenon didn’t happen in the CSK-chitosan NPs group. Since the CSK-chitosan NPs had fewer irritation to the animals. 0 2 4 6 8 10 12 0 20 40 60 80 100 120 140 160 180 200 220 240 260

Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice

Exenatide Prevents High-Glucose-induced Damage of Retinal Ganglion Cells Through a Mitochondrial Mechanism

Exenatide Exerts Direct Protective Effects on Endothelial Cells Through the AMPK/Akt/eNOS Pathway in a GLP-1 Receptor-Dependent Manner.

The GLP-1 Analogue Exenatide Improves Hepatic and Muscle Insulin Sensitivity in Diabetic Rats: Tracer Studies in the Basal State and During Hyperinsulinemic-Euglycemic Clamp.

Effects of Exenatide Therapy on Insulin Resistance in the Skeletal Muscles of High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats.

Effects of Exenatide on Lipid Metabolism of Adipose Tissue in Diabetic Rats

Exenatide Mitigates Inflammation and Hypoxia along with Improved Angiogenesis in Obese Fat Tissue.

2106-P: Glucagon-Like Peptide-1 Receptor Agonist Exenatide Promotes ß-Cell Function via Activation of PPARd/UCP-2 Pathway

Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures

Pharmacokinetic/pharmacodynamic Studies on Exenatide in Diabetic Rats

Exenatide exerts a neuroprotective effect against diabetic cognitive impairment in rats by inhibiting apoptosis: Role of the JNK/c‐JUN signaling pathway

Dose–response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats

Exenatide Treatment Decreases Fasting Fibroblast Growth Factor 21 Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.

Exenatide Attenuates Non-Alcoholic Steatohepatitis by Inhibiting the Pyroptosis Signaling Pathway

Exenatide Induces Impairment of Autophagy Flux to Damage Rat Pancreas

Exenatide Treatment Increases Serum Irisin Levels in Patients with Obesity and Newly Diagnosed Type 2 Diabetes.

Effect of New Antidiabetics on Steatosis in Nerve Tissues and Nerve Conduction Velocity: Possible Role of Nerve Growth Factor (NGF)/Synaptophysin and Nrf2/HO-1 Pathways

The Glucose-Lowering Potential of Exenatide Delivered Orally via Goblet Cell- Targeting Nanoparticles

Extended Exenatide Administration Enhances Lipid Metabolism And Exacerbates Pancreatic Injury In Mice On A High Fat, High Carbohydrate Diet

Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy

The glucose-lowering potential of exenatide orally delivered via a goblet cell-targeting nanoparticles